Please assess the completion status of the following clinical trial:

Trial Title: Campath Maintenance in Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment in this study is open to patients 18 years of age with confirmed chronic lymphocytic leukemia, a clinical response of stable disease or better to previous treatment, and an Eastern Cooperative Oncology Group performance status of 0-2~Exclusion Criteria:~* Treatment failure in more than 3 prior regimens~* Active secondary malignancy~* Central nervous system involvement with CLL~* History of significant allergic reaction to antibody therapies that required discontinuation of the antibody therapy~* History of HIV positivity~* Hepatitis C virus (HCV) positivity based upon core antigen testing~* Active infection, requiring treatment with antibiotic, antiviral, or antifungal agents~* Pregnancy or lactation~* Other severe, concurrent diseases or mental disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Campath maintenance treatment (Type: OTHER): Single arm, open label trial of Campath on a maintenance schedule for patients who have had a response to prior conventional chemotherapy. Treatments consist of dose escalation (3, 10 and 30mg) during week 1 followed by weekly dosing of Campath at 30 mg once weekly for 7 weeks followed by Campath 30 mg every 2 weeks for 16 weeks followed by Campath 30 mg once every 3 weeks for 24 weeks. Total duration of treatment up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).